KLRA Share Price Performance
US$11.99
-14.01 (-53.88%)
71.7% undervalued intrinsic discount
US$42.40
Fair Value
Price US$11.99
AnalystConsensusTarget US$42.40
Fair ValueUS$42.40
Share Pricen/a
Seeking Alpha • Sep 17
Kailera Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
KLRA Community Narratives
AN
Fair Value
·Fair Value US$42.4 71.7% undervalued intrinsic discount
Late Stage Obesity Pipeline Progress Will Drive Long Term Upside Potential
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Kailera Therapeutics
71.7% undervalued intrinsic discount
New
Late Stage Obesity Pipeline Progress Will Drive Long Term Upside Potential
View narrativeAN
Published 21 Sep
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Late Stage Obesity Pipeline Progress Will Drive Long Term Upside Potential
Fair Value: US$42.4 71.7% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Kailera Therapeutics, Inc. Key Details
About KLRA
- Founded
- 2024
- Employees
- 145
- CEO
- WebsiteView website
Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
